{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:27Z","timestamp":1792783407441,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007231","name":"Cancerf\u00f6reningen i Stockholm","doi-asserted-by":"publisher","award":["19 0510 Pj."],"award-info":[{"award-number":["19 0510 Pj."]}],"id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Institute of Technology","id":[{"id":"https:\/\/ror.org\/026vcq606","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the feasibility and predictive value in performing ex vivo drug sensitivity testing on bone sarcomas from patients with refractory disease and identify agents with potential therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of 7 osteosarcomas (OS) and 4 Ewing sarcoma (ES) patient-derived cells (PDCs) were screened against a library of oncological drugs, gene panel sequencing and mRNA expression arrays. Drug responses were correlated to the molecular characteristics of specific sarcoma subtypes and patient response to therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      OS PDCs showed heterogeneous drug sensitivity, with observed responses for mTOR, PKC, MAPK and CDK inhibitors that correlated with the histological subtype and genotype of the primary tumor. Two of 4 ES PDCs displayed morphological dichotomy as separate\n                      <jats:italic>Ews-Fli1<\/jats:italic>\n                      positive spheroid and adherent populations. These ES PDCs showed comparable responses to most of the oncological drugs but differential sensitivity to rapalogs and SMAC-mimetics. In both, OS and ES, the drug sensitivity of PDCs correlated to the patient response to chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Drug sensitivity testing of PDCs from bone sarcomas is a valuable tool for a rapid identification of potential treatments, in otherwise genetically complex group of tumors where genome-based assays are difficult to implement. Clones with different phenotypes can outgrow in PDC cultures and can represent clonal evolution that give raise to tumor recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04261-4","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:18:42Z","timestamp":1776086322000},"page":"4873-4884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1247-7028","authenticated-orcid":false,"given":"Christina","family":"Linder-Stragliotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-6067","authenticated-orcid":false,"given":"Panagiotis","family":"Tsagkozis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2778-6918","authenticated-orcid":false,"given":"Swapnil","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Alicia","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-1359","authenticated-orcid":false,"given":"Bertha Alicia","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"4261_CR1","unstructured":"WHO classification of bone and soft tissue sarcomas, vol. 3 (5th edition). Lyon France: IARC Press; 2020."},{"issue":"11","key":"4261_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722\u201335.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4261_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/annonc\/mdu526","volume":"26","author":"JS Whelan","year":"2015","unstructured":"Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26(2):407\u201314.","journal-title":"Ann Oncol"},{"issue":"16","key":"4261_CR4","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1200\/JCO-24-01281","volume":"43","author":"H Hiraga","year":"2025","unstructured":"Hiraga H, Machida R, Kawai A, Kunisada T, Yonemoto T, Endo M, et al. Methotrexate, doxorubicin, and cisplatin versus methotrexate, doxorubicin, and cisplatin + ifosfamide in poor responders to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (JCOG0905): a multicenter, open-label, randomized trial. J Clin Oncol. 2025;43(16):1886\u201397.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4261_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000151310","volume":"122","author":"S Selvarajah","year":"2008","unstructured":"Selvarajah S, Yoshimoto M, Ludkovski O, Park PC, Bayani J, Thorner P, et al. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res. 2008;122(1):5\u201315.","journal-title":"Cytogenet Genome Res"},{"key":"4261_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051102","author":"M Shorokhova","year":"2021","unstructured":"Shorokhova M, Nikolsky N, Grinchuk T. Chromothripsis-explosion in genetic science. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10051102.","journal-title":"Cells"},{"key":"4261_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2407-4-45","volume":"4","author":"TK Man","year":"2004","unstructured":"Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer. 2004;4:45.","journal-title":"BMC Cancer"},{"issue":"1","key":"4261_CR8","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","volume":"13","author":"BA Nacev","year":"2022","unstructured":"Nacev BA, Sanchez-Vega F, Smith SA, Antonescu CR, Rosenbaum E, Shi H, et al. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nat Commun. 2022;13(1):3405.","journal-title":"Nat Commun"},{"key":"4261_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15936","volume":"8","author":"S Behjati","year":"2017","unstructured":"Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun. 2017;8:15936.","journal-title":"Nat Commun"},{"issue":"20","key":"4261_CR10","doi-asserted-by":"publisher","first-page":"11547","DOI":"10.1073\/pnas.1934852100","volume":"100","author":"M Overholtzer","year":"2003","unstructured":"Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A. 2003;100(20):11547\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4261_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34689-5","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Wang J, Sun M, Zuo D, Wang H, Shen J, et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun. 2022;13(1):7207.","journal-title":"Nat Commun"},{"issue":"12","key":"4261_CR12","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.1245\/s10434-022-12086-y","volume":"29","author":"SD Forsythe","year":"2022","unstructured":"Forsythe SD, Sivakumar H, Erali RA, Wajih N, Li W, Shen P, et al. Patient-specific sarcoma organoids for personalized translational research: unification of the operating room with rare cancer research and clinical implications. Ann Surg Oncol. 2022;29(12):7354\u201367.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4261_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48634-y","volume":"9","author":"P Nanni","year":"2019","unstructured":"Nanni P, Landuzzi L, Manara MC, Righi A, Nicoletti G, Cristalli C, et al. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Sci Rep. 2019;9(1):12174.","journal-title":"Sci Rep"},{"key":"4261_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2022.101911","volume":"79","author":"F Chen","year":"2022","unstructured":"Chen F, Zhang Z, Shen R, Chen M, Li G, Zhu X. Generation and characterization of patient-derived xenografts from patients with osteosarcoma. Tissue Cell. 2022;79:101911.","journal-title":"Tissue Cell"},{"issue":"5","key":"4261_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1056\/NEJM199408043310503","volume":"331","author":"O Delattre","year":"1994","unstructured":"Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331(5):294\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"4261_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","volume":"4","author":"F Tirode","year":"2014","unstructured":"Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014;4(11):1342\u201353.","journal-title":"Cancer Discov"},{"issue":"11","key":"4261_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/2159-8290.CD-13-1037","volume":"4","author":"BD Crompton","year":"2014","unstructured":"Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326\u201341.","journal-title":"Cancer Discov"},{"issue":"7","key":"4261_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004475","volume":"10","author":"AS Brohl","year":"2014","unstructured":"Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10(7):e1004475.","journal-title":"PLoS Genet"},{"issue":"6","key":"4261_CR19","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.celrep.2020.01.049","volume":"30","author":"MM Aynaud","year":"2020","unstructured":"Aynaud MM, Mirabeau O, Gruel N, Grossetete S, Boeva V, Durand S, et al. Transcriptional programs define intratumoral heterogeneity of ewing sarcoma at single-cell resolution. Cell Rep. 2020;30(6):1767\u201379 e6.","journal-title":"Cell Rep"},{"issue":"4","key":"4261_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41416-018-0359-4","volume":"120","author":"BA Brodin","year":"2019","unstructured":"Brodin BA, Wennerberg K, Lidbrink E, Brosjo O, Potdar S, Wilson JN, et al. Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. Br J Cancer. 2019;120(4):435\u201343.","journal-title":"Br J Cancer"},{"issue":"W1","key":"4261_CR21","doi-asserted-by":"publisher","first-page":"W57","DOI":"10.1093\/nar\/gkad390","volume":"51","author":"S Potdar","year":"2023","unstructured":"Potdar S, Ianevski F, Ianevski A, Tanoli Z, Wennerberg K, Seashore-Ludlow B, et al. Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data. Nucleic Acids Res. 2023;51(W1):W57\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4261_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/cjp2.219","volume":"7","author":"S De Noon","year":"2021","unstructured":"De Noon S, Ijaz J, Coorens TH, Amary F, Ye H, Strobl A, et al. MYC amplifications are common events in childhood osteosarcoma. J Pathol Clin Res. 2021;7(5):425\u201331.","journal-title":"J Pathol Clin Res"},{"issue":"21","key":"4261_CR23","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.1158\/1078-0432.CCR-18-4032","volume":"25","author":"Y Suehara","year":"2019","unstructured":"Suehara Y, Alex D, Bowman A, Middha S, Zehir A, Chakravarty D, et al. Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clin Cancer Res. 2019;25(21):6346\u201356.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4261_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1186\/s12885-025-14130-y","volume":"25","author":"A Assi","year":"2025","unstructured":"Assi A, Farhat M, Mohanna R, Hachem MCR, Zalaquett Z, Aoun M, et al. Tyrosine kinase inhibitors in Ewing\u2019s sarcoma: a systematic review. BMC Cancer. 2025;25(1):735.","journal-title":"BMC Cancer"},{"issue":"3","key":"4261_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00019606-199309000-00004","volume":"2","author":"M Ladanyi","year":"1993","unstructured":"Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol. 1993;2(3):163\u20137.","journal-title":"Diagn Mol Pathol"},{"key":"4261_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00334","volume":"7","author":"AE Marinoff","year":"2023","unstructured":"Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical targeted next-generation panel sequencing reveals MYC amplification is a poor prognostic factor in osteosarcoma. JCO Precis Oncol. 2023;7:e2200334.","journal-title":"JCO Precis Oncol"},{"key":"4261_CR27","volume":"13","author":"C Thompson","year":"2021","unstructured":"Thompson C, Hakim MO, Infante-Mendez J, Kesmodel S, Goel N. Radiation-associated sarcoma of the breast in a patient with a germline tumor protein p53 mutation. Cureus. 2021;13:e18563.","journal-title":"Cureus"},{"issue":"2","key":"4261_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","volume":"171","author":"B Faubert","year":"2017","unstructured":"Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, et al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358\u201371 e9.","journal-title":"Cell"},{"key":"4261_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020406","author":"E Morrish","year":"2020","unstructured":"Morrish E, Brumatti G, Silke J. Future therapeutic directions for Smac-mimetics. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9020406.","journal-title":"Cells"},{"key":"4261_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.25.542375","author":"A Al Shihabi","year":"2023","unstructured":"Al Shihabi A, Tebon PJ, Nguyen HTL, Chantharasamee J, Sartini S, Davarifar A, et al. The landscape of drug sensitivity and resistance in sarcoma. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.05.25.542375.","journal-title":"bioRxiv"},{"issue":"10","key":"4261_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216001","volume":"14","author":"MT Meister","year":"2022","unstructured":"Meister MT, Groot Koerkamp MJA, de Souza T, Breunis WB, Frazer-Mendelewska E, Brok M, et al. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. EMBO Mol Med. 2022;14(10):e16001.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"4261_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01556-3","volume":"17","author":"DJ Jung","year":"2024","unstructured":"Jung DJ, Byeon JH, Kim YC, Jeong WS, Choi JW, Jeong GS. Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment. J Hematol Oncol. 2024;17(1):35.","journal-title":"J Hematol Oncol"},{"key":"4261_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216028","volume":"554","author":"S Grissenberger","year":"2023","unstructured":"Grissenberger S, Sturtzel C, Wenninger-Weinzierl A, Radic-Sarikas B, Scheuringer E, Bierbaumer L, et al. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1\/BCL-X(L) inhibition against Ewing sarcoma. Cancer Lett. 2023;554:216028.","journal-title":"Cancer Lett"},{"key":"4261_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040879","author":"G Domenici","year":"2021","unstructured":"Domenici G, Eduardo R, Castillo-Ecija H, Orive G, Montero Carcaboso A, Brito C. PDX-derived Ewing\u2019s sarcoma cells retain high viability and disease phenotype in alginate encapsulated spheroid cultures. Cancers (Basel). 2021;13(4). https:\/\/doi.org\/10.3390\/cancers13040879.","journal-title":"Cancers (Basel)"},{"key":"4261_CR35","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.19.524562","author":"CR Schott","year":"2023","unstructured":"Schott CR, Koehne AL, Sayles LC, Young EP, Luck C, Yu K, et al. Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.01.19.524562.","journal-title":"bioRxiv"},{"issue":"11","key":"4261_CR36","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/neuonc\/noad097","volume":"25","author":"AT Larsson","year":"2023","unstructured":"Larsson AT, Bhatia H, Calizo A, Pollard K, Zhang X, Conniff E, et al. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. Neuro Oncol. 2023;25(11):2044\u201357.","journal-title":"Neuro Oncol"},{"issue":"6","key":"4261_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/os.13211","volume":"14","author":"M Sun","year":"2022","unstructured":"Sun M, Wang Z, Sun W, Chen M, Ma X, Shen J, et al. Correlation between patient-derived xenograft modeling and prognosis in osteosarcoma. Orthop Surg. 2022;14(6):1161\u20136.","journal-title":"Orthop Surg"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04261-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04261-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04261-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:41:14Z","timestamp":1790160074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04261-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4261"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04261-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The presented research was conducted in accordance with the Declaration of Helsinki with the ethical standards that ensure respect and integrity for all human subjects that participated and justified by the potential benefit to the patient. The collection and use of biopsy material for molecular studies was approved by the Central Ethical Review Board in Stockholm (regionala etikpr\u00f6vningsn\u00e4mnden) No. 2013\u20131979-31\u20133 and No. 2018\u2013198-31\u20131. All patients were informed prior to surgery\/biopsy and gave consent for using their tumour samples during and after the study.","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}